Trinity Biotech plc (NASDAQ:TRIB) shares were up 6.3% during mid-day trading on Wednesday . The company traded as high as $12.97 and last traded at $12.78, with a volume of 95,495 shares trading hands. The stock had previously closed at $12.02.

Separately, Zacks Investment Research upgraded Trinity Biotech plc from a “sell” rating to a “hold” rating in a research report on Wednesday, June 22nd. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $17.00.

The firm has a 50 day moving average of $12.13 and a 200-day moving average of $11.29. The stock has a market cap of $299.90 million and a P/E ratio of 55.45.

Trinity Biotech plc (NASDAQ:TRIB) last posted its quarterly earnings results on Thursday, July 21st. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.03. The firm had revenue of $26.30 million for the quarter, compared to the consensus estimate of $24.30 million. On average, equities analysts anticipate that Trinity Biotech plc will post $0.14 EPS for the current year.

An institutional investor recently raised its position in Trinity Biotech plc stock. Stephens Inc. AR boosted its stake in Trinity Biotech plc (NASDAQ:TRIB) by 4.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 123,171 shares of the company’s stock after buying an additional 5,045 shares during the period. Stephens Inc. AR owned approximately 0.53% of Trinity Biotech plc worth $1,448,000 as of its most recent filing with the SEC.

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.